Psilocybin Therapy Statistics in US 2026 | Users, States & Key Facts

What Is Psilocybin Therapy?

Psilocybin therapy — the supervised therapeutic use of psilocybin, the naturally occurring psychedelic compound found in certain species of mushrooms — has moved from the fringes of psychiatric research to one of the most closely watched frontiers in American medicine in the span of approximately a decade. Psilocybin is a serotonergic hallucinogen that acts primarily on the brain’s 5-HT2A serotonin receptors, producing alterations in perception, emotion, and cognition that typically last four to six hours and which, under properly designed therapeutic conditions, have demonstrated in clinical trials the capacity to produce lasting improvements in depression, anxiety, addiction, and end-of-life distress that far exceed what conventional antidepressants and therapy produce. The compound is not new — it has been used in indigenous healing and ceremonial contexts across Mesoamerica and elsewhere for thousands of years, and Western science began studying it in the 1950s and 1960s before the passage of the Controlled Substances Act of 1970 classified it as a Schedule I substance, effectively halting research for several decades. The modern evidence base for psilocybin therapy was rebuilt, largely from scratch, beginning in the late 1990s at institutions including Johns Hopkins University, the Imperial College London, and New York University, culminating in the FDA granting psilocybin Breakthrough Therapy Designation for treatment-resistant depression (TRD) in 2018 and for major depressive disorder (MDD) in 2019 — formal regulatory acknowledgments that the compound showed “substantial improvement over available therapies” in early clinical evidence. Since those designations, the pace of trial completion, regulatory movement, and state-level legislative action has been accelerating faster than at any point since prohibition began.

As of March 29, 2026, psilocybin therapy in America stands at a genuinely historic inflection point. Yesterday — March 28, 2026 — CNN published a landmark 4,000-word investigation documenting that 5,935 clients received psilocybin services through Oregon’s state-regulated program in 2025, making that single year’s patient count for one state alone the largest publicly documented cohort of legally treated psilocybin therapy recipients in US history. Colorado — the second state to legalize psilocybin with a 2023 law — has issued its first healing centre licences and is beginning patient services. New Mexico has established a Medical Psilocybin Program now in development, with patient access expected by December 2026. COMPASS Pathways — the UK-based company whose synthetic psilocybin drug COMP360 is furthest along the FDA approval pathway — recently announced positive Phase 3 trial results and is preparing to file a New Drug Application with the FDA, a filing that could produce the first-ever FDA approval of a psilocybin drug product in the not-too-distant future. The Drug Enforcement Administration (DEA) has dramatically increased its legally produceable psilocybin quotas in January 2026 — a regulatory signal of intent as much as a practical capacity measure. And a RAND survey of 10,122 US adults published in 2025 found that approximately one quarter (25%) of Americans now support legal use of psilocybin mushrooms — a support level the RAND researchers compared to cannabis support levels in the mid-1990s, just before states began enacting medical marijuana laws. The trajectory is unmistakable, even if the destination and timeline remain genuinely uncertain.

Interesting Key Facts About Psilocybin Therapy Statistics in the US 2026

Source: CNN — “Thousands of Americans Were Treated With Psilocybin in 2025” (published March 28, 2026 — yesterday; Slashdot summary March 28, 2026); RAND Corporation — “RAND 2025 Psychedelics Survey” (published 2026, data collected September–October 2025, n=10,122 US adults); ASTHO — “Policy Trends Shaping Behavioral Health in 2026” (December 8, 2025)

The Oregon patient statistics — 5,935 clients in 2025 — are the most grounding and concrete number in all of psilocybin therapy statistics in 2026, because they represent real people who legally received psilocybin services in a real, state-regulated programme, not clinical trial participants or underground therapy clients. Oregon’s Measure 109, passed by voters in 2020 and operational since 2023, created the world’s first state-level regulated market for supervised psilocybin services outside of a clinical trial framework — a genuinely unprecedented regulatory experiment. The 5,935 figure makes Oregon’s 2025 cohort the largest documented cohort of legally treated psilocybin service recipients in US history and provides the field with something it has badly needed: real-world data on who accesses these services, what outcomes they report, and what operational challenges arise at scale. It is a number the FDA, state legislatures across the country, and international regulators are watching closely.

The RAND survey finding that 25% of Americans now support legal psilocybin use is the most important public opinion benchmark available, and the RAND researchers’ comparison to cannabis support in the mid-1990s is a historically loaded analogy. In 1995, cannabis had roughly 25% public support for legalization — and within a decade, medical marijuana laws had passed in multiple states, and within two decades, recreational legalization had followed in Oregon, Colorado, Washington, and Alaska. RAND’s data was the first survey to ask about individual psychedelic substances rather than psychedelics as a general category, and the fact that psilocybin at 25% support dwarfs LSD and MDMA at just 10% each tells a story about how the therapeutic framing of psilocybin — distinct from other substances — has successfully built public legitimacy in a way that other psychedelics have not yet achieved.

Psilocybin Therapy by State Statistics in the US 2026

Psilocybin Legal Status by State — Regulated, Decriminalized, Active Legislation

Source: CNN (March 28, 2026); ASTHO (December 8, 2025); Mycomeditations (February 5, 2026); PNW Spore (January 2, 2026); Magic Mushrooms Shop IT Blog (March 2026); King & Spalding (2025)

The state-by-state map of psilocybin therapy in America in 2026 reveals a regulatory landscape that is moving more rapidly than at any point since psilocybin was first prohibited in 1970 — and doing so in a deliberately fragmented, cautious, and evidence-anchored way that mirrors the early trajectory of medical marijuana far more closely than advocates of rapid legalization would prefer and far more quickly than opponents ever anticipated. The “more than two dozen states considered and seven states passed measures” on psilocybin in 2025 alone — confirmed by ASTHO’s December 2025 policy tracking — makes 2025 the most legislatively active year in psilocybin policy history by a considerable margin. The Iowa House’s 84–6 passage of a predecessor bill that has now become the basis for an American Legislative Exchange Council (ALEC) model bill influencing legislation in other states is particularly significant: ALEC’s involvement means psilocybin legislation is now being promoted through the same conservative state legislative infrastructure that helped accelerate drug policy reforms (particularly criminal justice reforms) across red states in the 2010s.

The veto decisions in Iowa and Virginia are equally instructive, because they reveal the most politically respectable way for governors to manage the psilocybin question in 2026: not by opposing psilocybin therapy outright, but by saying the state should wait for FDA approval and DEA rescheduling before acting unilaterally. This position — therapeutically supportive but procedurally deferential to federal regulators — will likely become the dominant political framing for psilocybin in most states over the next 12 to 18 months, as COMPASS Pathways’ NDA submission to the FDA moves closer. Once an FDA-approved psilocybin product exists, the political and regulatory barrier to prescribing in every state that has passed a “pending FDA approval” framework evaporates automatically — meaning the work being done in Arizona, Colorado, and Nebraska in 2025 may prove to be prescient preparation for a much larger shift in the not-too-distant future.

Psilocybin Clinical Trial & FDA Statistics in the US 2026

Clinical Trial Pipeline — FDA Designations, Phase 3 Trials & Key Data

Source: PMC — PMC11016263 (134 trial analysis); PMC — PMC11907663 (FDA pipeline review); CNN (March 28, 2026); UC Berkeley Microdose newsletter (2026); Emory University (November 2024); King & Spalding (2025); Magic Mushrooms Shop IT (March 2026)

The clinical trial statistics tell a story of extraordinary scientific breadth combined with regulatory caution. The 134 psilocybin trials across 54 conditions listed on ClinicalTrials.gov over the past two decades represent the most diverse clinical investigation of any single psychedelic compound in history — but the PMC analysis published in 2024 that documented these trials also issued a cautionary finding: most have been small, unblinded studies of 10 to 20 participants recruited over years at a single site, and the “hundreds of psilocybin clinical trials initiated…comprising a myriad of potential indications may actually be slowing this potential game-changing mental health therapeutic’s approval and is costing excessive amounts of capital.” The fragmentation of the trial evidence base — too many indications, too many small trials — has historically been one of the arguments the FDA has made when declining to expedite regulatory action. The COMPASS Pathways Phase 3 programme was specifically designed to address this critique: large, multi-site, rigorous Phase 3 trials with proper blinding and control groups, targeting the single indication (TRD) for which the evidence base is deepest, with the explicit goal of a regulatory approval that creates a legal precedent for the entire field.

The FDA’s 2026 policy change to a single Phase 3 trial default for NDA approval — delivered by FDA Commissioner Makary and published in the agency’s official commentary — has received surprisingly little mainstream press coverage relative to its significance for psilocybin specifically. If COMPASS secures approval on the strength of its Phase 3 programme, and if the one-trial standard means Usona Institute’s completed single Phase 3 trial could support its own NDA, the path from “no FDA-approved psilocybin” to “two FDA-approved psilocybin products for different indications” could compress from years to months. Dr. Lynn Marie Morski of the Psychedelic Medicine Association was not being hyperbolic when she told CNN on March 28, 2026, that psilocybin is “knocking on the door of FDA approval.” The door is closer than it has ever been — but the timing and outcome of the knock remain genuinely uncertain.

Psilocybin Therapy Efficacy & Treatment Statistics in the US 2026

Clinical Efficacy Data — Depression, PTSD, Addiction & Key Outcomes

Source: CNN — Dr. Albert Garcia-Romeu, Johns Hopkins (March 28, 2026); Emory University (November 2024); PMC (PMC11016263, PMC11907663); UC Berkeley Microdose (2026); Mycomeditations (February 5, 2026); Magic Mushrooms Shop IT (March 2026); King & Spalding (2025); Oregon OHA programme data

The efficacy statistics for psilocybin therapy are the reason this otherwise marginal and legally complex treatment is receiving the attention of mainstream medicine, federal regulators, and state legislatures simultaneously. The signal that drew the FDA to grant Breakthrough Therapy Designation in 2018 and 2019 was not ambiguous: in carefully controlled Phase 2 trials, psilocybin produced responses in patients with treatment-resistant depression that were substantially larger, longer-lasting, and faster-acting than those seen with conventional antidepressants. The Emory University study’s finding that a single 25 mg dose of psilocybin is often sufficient to reduce depression symptoms — and that this single-dose efficacy could make psilocybin dramatically more cost-efficient than years of ongoing antidepressant prescriptions and therapy — has significant implications for insurance economics that payers, health systems, and policymakers are beginning to model seriously.

The Johns Hopkins research finding two distinct biological hypotheses for how psilocybin works — either by disrupting entrenched neural traffic patterns (the “default mode network” disruption hypothesis, supported by neuroimaging studies) or through anti-inflammatory mechanisms (a newer hypothesis gaining scientific traction) — reflects the honest state of the science: psilocybin demonstrably produces lasting improvements in multiple clinical trials, but exactly why it does so is not yet fully understood. This mechanistic uncertainty has not prevented regulatory progress — the FDA does not require a complete mechanistic explanation for approval, only demonstrated safety and efficacy — but it does complicate the field’s ability to predict which patients will respond best and to optimize protocols accordingly. The Australia programme’s achievement of zero serious adverse events in 47 patients through September 2025 provides real-world safety data from a national prescribing programme that goes beyond the controlled trial setting and is being closely watched by FDA regulators as preliminary evidence of the treatment’s safety profile at a population level.

Psilocybin Therapy Public Opinion & Market Statistics in the US 2026

RAND Survey, Market Size, Economic Projections & Public Attitudes

Source: RAND Corporation — 2025 Psychedelics Survey (n=10,122, data collected Sep–Oct 2025); CNN (March 28, 2026); Emory University (November 2024); Mycomeditations (February 5, 2026); Magic Mushrooms Shop IT (March 2026); King & Spalding (2025); NIMH depression data; Oregon OHA programme data

The RAND survey findings are the most important public opinion data point in psilocybin policy analysis in 2026, and they deserve careful interpretation. When RAND’s lead author Ben Senator said that support for legalizing psilocybin is “similar to attitudes towards cannabis in the mid-1990s, before states began implementing medical marijuana laws” — he was making a historically weighted analogy. The cannabis trajectory from the mid-1990s forward shows that a 25% support baseline, when combined with a compelling medical narrative, active state-level experimentation, a growing evidence base from legalized states, and shifting demographic composition of the electorate (younger voters being more supportive), can reach majority support within 10 to 15 years and produce substantial legislative change well before that. The fact that the RAND survey found the distinction between different psychedelic substances to be statistically significant — psilocybin at 25%, MDMA and LSD at approximately 10% each — validates the strategy that psilocybin advocates have pursued of keeping psilocybin’s public image tied specifically to the therapeutic and mental health context rather than recreational or counterculture associations.

The cost of psilocybin therapy in Oregon’s regulated market — reportedly $1,000 to $3,500 per session, entirely out-of-pocket with no insurance coverage — is the most significant access equity barrier currently documented in the legal psilocybin landscape. Unlike a prescription antidepressant that might cost $10 to $50 per month through insurance, a single psilocybin session at Oregon’s prevailing rates consumes the entire healthcare budget of many working-class Americans. This affordability crisis is well-recognised by Oregon policymakers and practitioners and has been cited as the primary reason that despite 5,935 clients accessing services in 2025, the demographic profile of Oregon psilocybin service clients skews heavily toward white, educated, and economically privileged Oregonians — a limitation that practitioners describe as fundamental and urgent. Any broader national programme that fails to address insurance coverage, sliding-scale fee structures, and access to service centres in rural and low-income communities will reproduce and amplify these inequalities at national scale.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE